Oculis Holding AG (OCS) Shares Outstanding (Weighted Average) (2021 - 2026)
Quarterly Shares Outstanding (Weighted Average) rose 28.26% to $791.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $791.7 million through Mar 2026, up 28.26% year-over-year, with the annual reading at $734.4 million for FY2025, 44.26% up from the prior year.
Oculis Holding AG's Shares Outstanding (Weighted Average) history spans 6 years, with the latest figure at $791.7 million for Q1 2026.
- Shares Outstanding (Weighted Average) came in at $791.7 million for Q1 2026, up from $734.4 million in the prior quarter.
- In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $791.7 million in Q1 2026 to a low of $4.0 million in Q4 2022.
- The 5-year median for Shares Outstanding (Weighted Average) is $495.2 million (2024), against an average of $482.9 million.
- Year-over-year, Shares Outstanding (Weighted Average) soared 3360.76% in 2022 and then grew 16.63% in 2024.
- Oculis Holding AG's Shares Outstanding (Weighted Average) stood at $4.0 million in 2022, then soared by 921.99% to $41.3 million in 2023, then surged by 1132.22% to $509.1 million in 2024, then skyrocketed by 44.26% to $734.4 million in 2025, then rose by 7.8% to $791.7 million in 2026.
- Per Business Quant, the three most recent readings for OCS's Shares Outstanding (Weighted Average) are $791.7 million (Q1 2026), $734.4 million (Q4 2025), and $698.8 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 177,333.76 Bn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | 185,491.37 Bn |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 100.00 Bn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | 55.66 Bn |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 254.10 Mn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 104.00 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | 16.04 Bn |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 132.89 Mn |
| 10 | Oculis Holding AG | 24.51 Bn | 24.21 Bn | - | 791.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 791.74 Mn |
| Dec 31, 2025 | 734.44 Mn |
| Sep 30, 2025 | 698.81 Mn |
| Jun 30, 2025 | 674.00 Mn |
| Mar 31, 2025 | 617.30 Mn |
| Dec 31, 2024 | 509.12 Mn |
| Sep 30, 2024 | 495.15 Mn |
| Jun 30, 2024 | 472.17 Mn |
| Mar 31, 2024 | 420.47 Mn |
| Dec 31, 2023 | 41.32 Mn |
| Sep 30, 2023 | 414.37 Mn |
| Jun 30, 2023 | 404.83 Mn |
| Dec 31, 2022 | 4.04 Mn |
| Dec 31, 2021 | -123,983.53 |